Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.

PHASE3CompletedINTERVENTIONAL
Enrollment

1,138

Participants

Timeline

Start Date

April 5, 2017

Primary Completion Date

June 29, 2018

Study Completion Date

June 29, 2018

Conditions
Acute Pain
Interventions
DRUG

MR308

two times daily; Mode of Administration:oral

DRUG

MR308

four times daily; Mode of Administration:oral

DRUG

MR308

two times daily; Mode of Administration:oral

DRUG

MR308

given four times daily to maintain the blind; Mode of Administration:oral

Trial Locations (8)

1106

Bajcsy-Zsilinszky Korhaz Szuleszet-Nogyogyaszati Osztaly, Budapest

1632

"Multiprofile Hospital for Active Treatment - Doverie AD, Sofia Department of Gynecology", Sofia

4201

Vidzeme Hospital Department of Gynecology and Obstetrics, Valmiera

105203

Federal State Budgetary Institution National Medical-Surgical Centre named after N.I. Pirogov of the Ministry of Health of the Russian Federation Anesthesiology, Moscow

220007

Minsk City Gynecology Hospital Department of Gynecology, Minsk

N6A 5W9

Victoria Hospital - London Health Sciences Centre, London

37-700

Wojewódzki Szpital im. Św. Ojca Pio w Przemyślu Oddział Ginekologii i Położnictwa, Przemyśl

08916

Hospital Universitari Germans Trias i Pujol Anestesia y Reanimación, Barcelona

All Listed Sponsors
lead

Mundipharma Research GmbH & Co KG

INDUSTRY

NCT03062644 - Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2. | Biotech Hunter | Biotech Hunter